Andrew Cittadine - 30 Sep 2024 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Operating Officer
Signature
/s/ Karthik Radhakrishnan , Attorney-in-fact
Issuer symbol
MNPR
Transactions as of
30 Sep 2024
Net transactions value
-$3,606
Form type
4
Filing time
02 Oct 2024, 19:44:01 UTC
Previous filing
02 Jul 2024
Next filing
02 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +1,791 +4.6% 40,404 30 Sep 2024 Direct F2
transaction MNPR Common Stock Tax liability $3,606 -535 -1.3% $6.74 39,869 30 Sep 2024 Direct F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -1,791 -12% $0.000000 12,864 30 Sep 2024 Common Stock 1,791 Direct F1, F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2 Represents shares acquired on vesting and settlement of restricted stock units.
F3 Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F4 On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5 On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.